Intl. Biotechnology Trust PLC
25 November 1999
The headline for the Intl. Biotechnology Trust PLC announcement released at
07:30 today should read 'Investment Report' and not 'Net Asset Value' as
originally shown. All other details are unchanged.
TOP INVESTMENTS LIFT INTERNATIONAL BIOTECHNOLOGY TRUST'S NET ASSET VALUE
Thursday 25 November 1999, London, UK Corporate and scientific developments at
International Biotechnology Trust's ('IBT') lead investments during November
helped lift the Trust's undiluted Net Asset Value per share from 78.23p at the
end of October to 93.42p on 15 November, a rise of 19.4%.
Biocompatibles International ('Biocompatibles'), IBT's largest current
investment by value, concluded a distribution agreement with Abbott
Laboratories Inc for the BiodivYsio stent on 22 November. Abbott will
exclusively distribute the Biocompatibles stent in the US. In addition,
Abbott received rights to Biocompatibles' pipeline of other interventional
vascular products and was granted a licence to Biocompatibles' proprietary
phosphorylcholine (PC) coating technology for other devices. On 15 November,
Biocompatibles' share price was 358.5p, having risen from 248.5p at the end of
October and 162.5p at the end of September. On the day of the announcement of
the Abbott agreement, the share price rose further, up to 380p.
On 8 November, Ribozyme Pharmaceuticals Inc ('Ribozyme'), IBT's second largest
investment, also rose in value with the presentation of the results of a study
which showed that a ribozyme therapeutic had potent activity against a
Hepatitis C virus in cell culture. Ribozyme's share price increased from US$
6 at the end of October to US$ 10.06 on 15 November.
Also contributing to IBT's increase in NAV was Medarex which has had positive
analyst coverage over recent months and, on 11 November, received a $1 million
access fee from Novartis for its HuMAb-Mouse technology. Medarex's share
price increased from US$ 6.88 at the end of October to US$ 10.75 on 15
November.
Details of the contributions of IBT's top ten investments to the Trust's NAV
are shown in the attached table. As stated above, Biocompatibles is now the
Trust's largest investment following the divestment of Pharmacia & Upjohn
('P&U') shares received through the acquisition of SUGEN by P&U.
For more information please contact:
Jeremy Curnock Cook, Director
International Biotechnology Trust plc
Tel: 0171 634 2881
E-mail: jeremy.curnock-cook@ramasset.co.uk
Website Address: www.internationalbiotrust.com
Sue Charles/Chris Gardner
HCC.De Facto Group plc
Tel: 0171 496 3300
E-mail: s.charles@hccdf.co.uk
Issued by International Biotechnology Trust plc and approved by Rothschild
Asset Management, which is regulated by IMRO
IBT'S TOP TEN INVESTMENTS BY VALUE
As at 15 November 1999
Value £000 Proportion of IBT's NAV
Core investments
Biocompatibles International 9,197 11.19%
Ribozyme Pharmaceuticals 8,060 9.80%
Cubist Pharmaceuticals 6,664 8.11%
Medarex 6,635 8.07%
Onyx Pharmaceuticals 6,194 7.53%
Angiotech Pharmaceuticals 3,512 4.27%
NetGenics * 3,406 4.14%
MorphoSys 3,222 3.92%
Corvas International 3,082 3.75%
Targeted Genetics 2,928 3.56%
* Unquoted investment
Unaudited NAV as at 15 November 1999 £82,215,837
Notes to editors:
International Biotechnology Trust plc
International Biotechnology Trust plc (IBT) was launched to take advantage of
the investment opportunities arising in mid-stage life-science companies,
involving a close working relationship with investee companies through the
provision of strategic management support and sector expertise.
International Biotechnology Trust Key Data
Founded in 1994
£69.2 million Net Asset Value at 31 August 1999
Listed on the London Stock Exchange
Invests in mid-stage life science companies
Investment criteria
- sound technology platform
- under-resourced
- good prospects for commercialisation
Further financing may be invested where appropriate
Strategic support and management development provided
16 core investments
- 11 in US, 3 in UK, 1 in Germany, 1 in Canada
IBT Management Company
The RBU, led by Jeremy Curnock Cook, was established in 1981 within RAM to act
in an advisory capacity to Biotechnology Investments Limited. In 1994, RBU
also became responsible for the management of IBT. The RBU team is
multidisciplinary, with backgrounds in science, industry, finance and
management, enabling it to provide comprehensive advice and support to
investee companies. The investment team works with a number of
internationally renowned scientific and industry consultants who help assess
new technologies and investment proposals as well as supporting investee
companies.
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.